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Abstract
Background: Despite their broadly recommended use as chemotherapeutic agents, the porphyrogenicity of
methotrexate and actinomycin D have not been confirmed. Accordingly, it is not known whether these agents are
safe for use in patients with porphyria.
Case presentation: In this report, we present a case of an invasive mole with lung metastasis in a 49-year-old
Japanese woman who had previously been diagnosed with acute intermittent porphyria at 27 years of age
but had no recent history of acute intermittent porphyria attacks. Her serum human chorionic gonadotropin
level was elevated 1 month after hysterectomy, and she was referred to our center for chemotherapy. After
she received 100 mg of methotrexate, drug eruptions were observed starting on day 3 and grew progressively worse.
Erythema and mucosal erosion spread throughout her body, whereupon she was administered prednisolone. In
addition, our patient experienced febrile neutropenia and required granulocyte colony- stimulating factor treatment.
No changes in our patient’s urinary coproporphyrin or uroporphyrin levels were detected during this entire episode.
Methotrexate was replaced by actinomycin D (0.5 mg/body intravenously on days 1–5 every 2 weeks). After five
uneventful cycles of actinomycin D, our patient achieved and maintained a normal serum human chorionic
gonadotropin level for 3 years.
Conclusions: Methotrexate and actinomycin D did not induce acute porphyric attacks in this patient with
acute intermittent porphyria; however, severe adverse effects were noted with methotrexate. Although further
investigation is required, our data suggest that these agents are nonporphyrinogenic and can therefore be
used to treat patients with comorbid porphyria.
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Background
In 2002, the International Federation of Gynecology and
Obstetrics (FIGO) 2000 staging and risk factor scoring
system, which recommends chemotherapy regimens for
gestational neoplasia, were published by the FIGO On-
cology Committee [1]. Among the recommendations,
methotrexate (MTX) and actinomycin D (ACT-D) were
the most commonly suggested chemotherapeutic drugs
in various regimens. The folic acid antagonist MTX is
most frequently used to treat gestational trophoblastic
disease (GTD) [2], as well as leukemia and other cancers
such as breast cancer and urothelial carcinoma. In
addition, different doses of MTX can be used to treat
rheumatoid arthritis and psoriasis vulgaris. However,
MTX has been known to induce various toxicities, in-
cluding interstitial pneumonia, hepatopathy, bone mar-
row suppression, bone destruction, stomatitis, and
gastric ulcer. In addition to GTD treatment, ACT-D is
used to treat Wilms’ tumor, Ewing sarcoma, and rhabdo-
myosarcoma; however, this agent has been reported to
induce hepatic vein obstruction.
Porphyrias comprise a collection of seven disorders
that result from genetic defects in heme biosynthesis.
The clinical management priorities for patients with por-
phyria include the prevention of acute attacks and avoid-
ance of skin lesions. Many factors have been identified
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to induce acute attacks, including porphyrinogenic drug
use, fasting, smoking, alcohol consumption, and infec-
tion, as well as emotional and physical stress [3]. Ac-
cordingly, specific precautions must be taken when
treating porphyric patients with malignant diseases in
order to minimize the risk of an acute porphyric attack
and to ensure optimal therapeutic effects against the ma-
lignancy. However, the porphyrinogenic or nonporphyri-
nogenic statuses of many chemotherapeutic drugs,
including MTX and ACT-D, have not yet been estab-
lished since the association of each chemotherapeutic
drug and acute intermittent porphyria (AIP) is very rare.
Therefore, it is essential that such data be accumulated
and reported.
The present report details our experience with the
treatment of an invasive mole with lung metastasis in a
Japanese patient with AIP. Although a severe drug
eruption as well as febrile neutropenia occurred in re-
sponse to MTX treatment, our patient successfully com-
pleted chemotherapy without experiencing a porphyric
crisis.
Case presentation
A 49-year-old Japanese woman (gravida 4, para 3) was
diagnosed with AIP at the age of 27. Our patient had re-
peatedly visited the hospital for stomachaches before-
hand; however, approximately 2 years of consultations
passed before she was accurately diagnosed. Afterwards,
she avoided elements known to precipitate acute attacks,
and had not experienced an acute porphyria attack since
she was 33 years of age. In addition, she began hyperten-
sion treatment with amlodipine besylate at the age of 40
years, and her last pregnancy had spontaneously aborted
4 years prior to the present event. In July 2011, this pa-
tient visited a local private clinic for atypical vaginal
bleeding and was referred to a general hospital because
of suspected spontaneous abortion. She was subse-
quently diagnosed with a acute intermittent porphyria
hydatidiform mole via dilatation and curettage (D&C).
One month after D&C, our patient presented with an
elevated serum human chorionic gonadotropin (hCG)
level (Fig. 1). As fertility preservation was deemed im-
possible, she underwent an abdominal total hysterec-
tomy. Pathological study of the resected specimen
revealed an invasive mole, but no metastasis was ob-
served. However, our patient’s serum hCG level was
again elevated 1 month after hysterectomy, and she was
referred to Saitama Medical Center for chemotherapy to
address expected AIP-associated complications. An X-
ray computed tomography scan of her chest, performed
at our institution, revealed a lung metastasis. The FIGO
2000 staging and risk factor scoring system indicated a
stage III:41 gestational trophoblastic neoplasia (GTN)
(Tables 1 and 2), and our patient was accordingly diag-
nosed with a low-risk GTN. Her treatment strategy in-
cluded intramuscular MTX administration at a dose of
20 mg/day for 5 days every 2 weeks.
MTX chemotherapy was initiated after our patient
provided informed consent, which included an under-
standing that MTX had not been implicated as either
porphyrinogenic or nonporphyrinogenic. Our patient ex-
perienced small eruptions on the hands and epigastric
region on day 3 of chemotherapy. However, a derma-
tologist did not interpret these eruptions as drug-related,
and thus treatment was continued. On day 5, the erup-
tions expanded over her whole body and worsened, with
ulcers developing on the oral mucosa (Fig. 2). Our pa-
tient was unable to eat or drink owing to the severe pain
caused by mucosal erosion; moreover, she complained of
painful micturition because of a sore on her vulva. A
skin biopsy revealed drug eruption instead of a porphy-
ric skin lesion. In particular, microabscesses had formed
Fig. 1 Changes in serum human chorionic gonadotropin (hCG) levels, urinary 8-carboxyl porphyrin (URO) and urinary 4-carboxyl porphyrin (COPRO)
during treatment. ACT-D actinomycin D, ATH abdominal total hysterectomy, D&C dilatation and curettage, MTX methotrexate
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under the stratum corneum, with neutrophilic and eo-
sinophilic invasion, and neutrophilic exocytosis was ob-
served in the epidermis. Liquefaction was also observed
between the epidermis and dermis, and eosinophilic,
neutrophilic, and lymphocytic invasion from the layer
between the epidermis and dermis to the superficial
layer of the dermis was noted (Fig. 3). No changes in
our patient’s urinary coproporphyrin or uroporphyrin
levels were observed despite the appearance of skin le-
sions (Fig. 1). She received intravenous prednisolone at
60 mg/day beginning on day 5 to treat the drug
eruption.
On day 11, our patient experienced febrile neutropenia
(absolute neutrophil count [ANC] on day 8 was 1,380/
μL but decreased to 12/μL on day 11) and was treated
subcutaneously with 75 μg/day of granulocyte-colony
stimulating factor (G-CSF) for 3 days beginning on day
11. However, as she was unable to recover from neutro-
penia (ANC remained at 12/μL on day 13), additional
subcutaneous G-CSF at 150 μg/day was administered for
2 days beginning on day 13, and her neutropenia finally
resolved on day 15 (ANC, 1598/μL). During that time,
her skin lesions and stomatitis also began to improve,
and the prednisolone dose was reduced to 40 mg/day.
As she was able to eat on day 17, oral prednisolone ad-
ministration at 20 mg/day was started on day 20 and ta-
pered on day 24. She was discharged on day 25.
Although our patient’s serum hCG level decreased
with MTX treatment, it became elevated during treat-
ment interruption. Chemotherapy with ACT-D was
therefore considered. After providing informed consent
to ACT-D treatment and acknowledging that ACT-D
was not implicated as either porphyrinogenic or nonpor-
phyrinogenic, our patient received intravenous ACT-D
at a dose of 1.5 mg/day on days 1–5 of every 2-week
period, starting on day 70 of her clinical course. As
shown in Fig. 1, her serum hCG level effectively de-
creased, and the lung metastasis disappeared without
any porphyric attacks. After five cycles of ACT-D, her
serum hCG level stabilized at 3.2 mIU/mL. Although
other chemotherapeutic drugs were considered, a nega-
tive serum hCG level was achieved and maintained for
the following 3 years.
Discussion
Porphyrias represent a collection of seven disorders
caused by inherent or acquired defects in genes related
to heme biosynthesis. The accumulation of intermediate
products such as porphobilinogen in the liver or skin in-
duces porphyric symptoms. Partial deficiency of any of
the seven enzymes in heme biosynthesis pathway results
in characteristic clinical and biochemical features
(Table 3), which are used to classify porphyrias into der-
matological, neuropsychiatric, and mixed forms. Porphy-
ria cutanea tarda (PCT) is the most common form, with
characteristic predominant cutaneous manifestations
such as photosensitivity. Neuropsychiatric (acute) por-
phyria is seen in AIP and plumboporphyria, and has
various manifestations, including acute attacks. Such
acute attacks are the most concerning manifestation of
porphyria and are known to be induced by certain drugs,
infection, alcohol consumption, smoking, fasting, and
stress.
To date, many porphyrinogenic drugs have been iden-
tified (Table 4) [4, 5]. Safe treatment of concomitant dis-
eases with nonporphyrinogenic drugs is the most
Table 1 FIGO 2000 risk factor scoring system for gestational trophoblastic neoplasia
Prognostic factors Score
0 1 2 4
Age (years) <40 ≥40
Antecedent pregnancy Mole Abortion Term
Interval from index pregnancy (months) <4 4–7 7–13 >13
Pretreatment serum hCG (IU/mL) <103 103–104 104–105 >105
Largest tumor size (including the uterus) (cm) <3 3−5 ≥5
Metastatic site Lung Spleen, kidney Gastrointestinal tract Liver, brain
Number of metastases 1−4 5−8 >8
Previous failed chemotherapy Single drug ≥2 drugs
Total score: ≤6, low risk; >7, high risk
FIGO International Federation of Gynecology and Obstetrics, hCG human chorionic gonadotropin, IU international unit
Table 2 FIGO 2000 staging for gestational trophoblastic
neoplasia (GTN)
FIGO staging
Stage I Disease confined to the uterus
Stage II GTN extends outside of the uterus, but is limited to genital
structures (adnexa, vagina, and broad ligament)
Stage III GTN extends to the lungs, with or without known genital tract
involvement
Stage IV Metastasis to other organ sites
FIGO International Federation of Gynecology and Obstetrics
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important aspect of preventing acute attacks. However,
some porphyrinogenic chemotherapeutic drugs without
alternative options might be required for malignant dis-
eases. A list of drugs known to be porphyrinogenic or
nonporphyrinogenic according to animal studies and
case reports is shown in Table 5 [6]. However, contradic-
ting reports exist for a number of chemotherapeutic
agents, including MTX.
Several case studies have reported an association be-
tween PCT and MTX therapy [7–9]. Most porphyria-
related drugs are thought to induce cytochrome P450
activity and thus increase the demand for hepatic heme
biosynthesis, leading to increased porphyrin formation.
However, as hepatic MTX metabolism does not involve
cytochrome P450, the association between MTX and
PCT cannot be explained by this mechanism. Addition-
ally, PCT lesions were reported to disappear despite
continued MTX therapy in at least one study [10].
Furthermore, experimental studies of chick embryos,
which are believed to reflect the human susceptibility to
drug-induced porphyria exacerbation, found no effects
of MTX on porphyrin metabolism [10]. In our case,
MTX induced severe cutaneous lesions that were histo-
pathologically diagnosed as a drug eruption rather than
porphyria. Drug eruption is a common adverse effect of
various types of nonchemotherapeutic drugs, and it was
highly unlikely that there was any relationship between
cutaneous symptoms and porphyria in our patient be-
cause no changes in her urinary coproporphyrin or uro-
porphyrin levels were observed throughout her episode.
Thus, MTX appeared to be nonporphyrinogenic in our
case.
In contrast, ACT-D has been reported to be safe in
AIP patients [11]. No case reports have indicated an as-
sociation between this agent and porphyric attacks, and
ACT-D was safely used in the case presented herein.
Fig. 2 Progress of eruption. On day 6, erythema with infiltration appeared on the trunk (upper panel); blisters containing bloody serum developed on
our patient’s hands (middle panel), and erosive lesions and a furred tongue were observed in her mouth (lower panel). On day 8, the erythema became
brown (upper panel); bullous lesions were observed on her hands (middle panel), and mucosal erosion of her mouth continued (lower panel). On day
18, the erythema improved, leaving only pigmentation (upper panel); the bullous rash was epithelialized with scaling (middle panel), and some erosive
lesions became blood-filled blisters (lower panel)
Fig. 3 Abdominal skin biopsy. Microabscesses formed under the stratum corneum, with neutrophilic and eosinophilic invasion, and neutrophilic
exocytosis was observed in the epidermis (hematoxylin and eosin staining, ×20 and ×40 magnification)
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Although more evidence from experimental studies and
case reports is needed for a definitive conclusion, we be-
lieve that ACT-D is a potentially nonporphyrinogenic
drug.
In cases not involving potentially porphyrinogenic che-
motherapeutic agents, stresses such as sepsis from neu-
tropenia and long fasting related to gastrointestinal
toxicity or pain [6] could also induce acute attacks.
Hematologic growth factors, including G-CSF, have been
reported to be safe for porphyria patients [12], and this
was true in our experience. Our results thus indicate
that G-CSF can help to prevent acute attacks resulting
from sepsis. Among commonly prescribed antiemetics,
the 5-hydroxytryptamine receptor antagonist ondanse-
tron and glucocorticoid are also considered safe for pa-
tients with porphyria [4, 5]. Additionally, dexamethasone
can be used safely, but no evidence is available regarding
aprepitant. Although alcohol consumption can induce a
porphyric attack, there are no reports on the safety of
taxane therapy in patients with porphyria.
Conclusions
In conclusion, given the rare nature of porphyrias,
knowledge regarding the safe use of chemotherapeutic
agents in these patients will require evidence from add-
itional case reports. We believe that our case contributes
to this knowledge and supports the use of MTX and
ACT-D as potentially nonporphyrinogenic chemothera-
peutic agents.
Patient’s perspective
I write the following to provide support for the case re-
port written about my treatment. I have no medical
knowledge or background so I can only write from my
own perspective and experience.
I was diagnosed with acute intermittent porphyria
(AIP) at 27 years of age. Prior to that, I had been treated
in ambulatory centers and hospitals many times for ab-
dominal pain, but the clinicians could not diagnose the
Table 3 Porphyria classification
Type of porphyria Enzyme inheritance Inheritance Clinical manifestation Urine concentration
Skin Neuropsychiatric







AD, 11q23 - +
+
Abdominal pain, neuropathy,
mental changes, and tachycardia
PBG σ-ALA
Congenital erythropoietic Uroporphyrinogen III synthase AR, 10q26 + - Skin lesion and hepatopathy
in early childhood
UPG I COPRO-gen I
Porphyria cutanea tarda Uroporphyrinogen
decarboxylase
AD, 1q34 ++ - Dark urine, occurring after
middle age
UPG
Hereditary coproporphyria Coproporphyrinogen oxidase AD, 9 + + Abdominal pain and peripheral,
neuropathy
PBG>ALA COPRO-gen III
Variegate porphyria Protoporphyrinogen oxidase 1q14 + + PBG>ALA COPRO-gen III
Erythropoietic
protoporphyria




AR autosomal recessive, ALA aminolevulinic acid, COPRO-gen coproporphyrinogen, AD autosomal dominant, PBG porphobilinogen, UPG uroporphyrinogen,
PP protoporphyrin
Table 4 Contraindicated medications in porphyria
Antimigraine agents: ergot preparation
Antipsychotic drugs: ethchlorvynol, glutethimide, hydroxyzine
Cardiocirculatory drugs: hydralazine, lidocaine, methyldopa,
spironolactone
Hormonal agents: danazol, progesterone
Analgesic drug: diclofenac
Anesthetic agent: barbiturate sedative
Antiseizure drugs: barbituric acid, carbamazepine, phenytoin,
sodium valproate
Antibiotic: chloramphenicol, clindamycin, erythromycin, rifampicin,
ketoconazole
Muscle relaxants: carisoprodol, orphenadrine
Respiratory drugs: clemastine, dimenhydrinate
Table 5 Carcinostatic medications and porphyria
Porphyrinogenic (chick studies):







Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine
arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine,
methotrexate, actinomycin D, cisplatin
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cause of this pain. Although I experienced very severe
pain, sometimes this was doubted and thought to be
caused by a mental disorder.
After I was diagnosed with AIP, the doctors told me
that many factors had been identified to induce acute at-
tacks, and I avoided these factors. I did not experience
any more abdominal pain attacks beginning at 33 years
of age; however, I felt uneasy about receiving
chemotherapy.
The doctors at Saitama Medical Center told me that
methotrexate (MTX) was most commonly used to treat
my disease (invasive mole with lung metastasis) but had
not been implicated as either porphyrinogenic or non-
porphyrinogenic, and therefore, they carefully treated
me with MTX.
On day 3 of the first chemotherapy course, I noticed
small eruptions on my hands and stomach, and reported
this to the doctors in charge. Next, the dermatology spe-
cialist visited me for an examination; he judged my skin
lesions to be mild drug-caused eruptions and allowed
the treatment to continue. On day 5, the eruptions ex-
panded over my whole body, and ulcers developed on
my oral mucosa. I could not eat or drink anything, not
even my own saliva. Each day, I discharged saliva onto
paper because I could not swallow it. For me, this period
when I could not drink and had a fever was the hardest.
Fortunately, however, I did not experience abdominal
pain similar to that in an AIP attack.
Two weeks after the initiation of chemotherapy, my
skin symptoms improved and I was gradually able to eat
a meal. My doctors said I would need to be treated with
another chemotherapeutic drug because my serum hCG
levels were elevated, but I wanted to go home at once
instead. Therefore, I was discharged from the hospital
after I became able to eat adequately.
My husband and I listened to an explanation about an-
other anticancer agent from a doctor in the outpatient
department 1 week later. She told us that the next medi-
cine, actinomycin D, had also not been evaluated for use
in patients with AIP. However, we understood the need
for chemotherapy, and we agreed to its use.
I was hospitalized again and received the new chemo-
therapy regimen. In contrast to my fear, it did not cause
any side effects. I continued to receive this therapy, be-
ing hospitalized and discharged again. My husband and I
were very happy to learn that my serum hCG levels had
decreased and the lung metastasis had disappeared.
After five rounds of chemotherapy with actinomycin D,
my serum hCG level plateaued at 3.2 mIU/mL. My doc-
tors told me about another chemotherapy, and I was
very disappointed. However, because I had been able to
receive the second chemotherapy with few side effects, I
convinced myself that I might survive the next
chemotherapy.
While the doctors prepared a new chemotherapeutic
drug, my serum hCG value fell below the cutoff value.
The doctor told me that I would usually need to receive
three additional courses of chemotherapy after the
serum hCG level fell below the cutoff level, but my
serum hCG level remained under the cutoff level 1
month after stopping the second chemotherapy. I had a
long conversation with my doctor, and we decided to
finish the chemotherapy at that time.
I began to work at an office 1 year after I finished this
treatment. I am currently living well.
I felt uneasy about using medicines for which the
safety in patients with AIP was unknown, so I will be
very happy if my experience will help other patients with
porphyria.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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